Heart-reactive antibody levels differentially associate with ventricular function in hereditary cardiomyopathies
6 affiliations
- 1Department of Clinical Research & Epidemiology, Comprehensive Heart Failure Center (CHFC), University Hospital Würzburg
- 2Institute for Virology and Immunobiology, University of Würzburg
- 3Institute for Clinical Epidemiology and Biometry, University of Würzburg
- 4Institute for Pharmacology and Toxicology, University of Würzburg
- 5Interdisciplinary Bank of Data and Biomaterials (ibdw), University Hospital Würzburg
- 6Department of Medicine I, University Hospital Würzburg
Abstract
Background gCMP are a major cause of cardiovascular morbidity and mortality. While agonistic anti-β1-adrenergic receptor antibodies (anti-β1AR-ECII) have a recognized pathogenic role in idiopathic dilated cardiomyopathy (DCM), the relevance of HRA in gCMP remains unclear. Methods One hundred gCMP patients with confirmed genetic variants in cardiomyopathy genes were compared with 100 age- and sex-matched healthy individuals. Antibody reactivities were quantified using bead-based flow cytometric assays against cardiac antigens: The second extracellular loop of the β1 adrenergic receptor (β1AR-ECII), Troponin I3 (TPI3), Tropomyosin 1 (TPM1), Myosin heavy chain 6 and 7 (MYH6, MYH7) and Myosin light chain 7 (MYL7). Results gCMP patients showed higher anti-TPI3 and lower anti-TPM1 antibody levels compared to controls indicating increased induction of the former and loss of the latter in gCMP patients. Age and sex influenced HRA patterns in both groups. Anti-MYH6 and anti-TPM1 antibody levels were negatively associated with left ventricular ejection fraction (LVEF), both overall and within specific gCMP subtypes, including hypertrophic and arrhythmogenic cardiomyopathy. Additionally, anti-MYH6 antibody levels were negatively associated with right ventricular function, measured by tricuspid annular plane systolic excursion (TAPSE). Conclusion Our findings stress the diagnostic potential of HRA profiling and indicate that gCMP patients might profit from therapeutic targeting of HRA.
Related
- Clinical and Genetic Characteristics of Hereditary Arrhythmias and Cardiomyopathies in the Middle East
- Different substitutions at the same β-myosin residue underlie divergent molecular phenotypes and distinct cardiomyopathies
- Patient-Derived hiPSC-Cardiomyocytes and Engineered Heart Tissues Reveal Distinct Functional Phenotypes in Inherited Cardiomyopathies
- Clinical Characteristics and Emergency Response to Sudden Cardiac Arrest/Death Secondary to Cardiomyopathies in Young Athletes
- Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling
BibTeX
@article{schiffer2026heartreactive,
title = {{Heart-reactive antibody levels differentially associate with ventricular function in hereditary cardiomyopathies}},
author = {Dennis Schiffer and Boshra Afshar and Daria Grosser and Juliana Pet and Lena Schmidbauer and Maximilian Bauser and Gustavo Ramos and Valerie Boivin-Jahns and Roland Jahns and Stefan Frantz and Peter Heuschmann and Stefan Störk and Brenda Gerull and Niklas Beyersdorf and Caroline Morbach},
journal = {BMC Cardiovascular Disorders},
year = {2026},
month = oct,
doi = {10.1186/s12872-026-06808-3},
url = {https://doi.org/10.1186/s12872-026-06808-3},
note = {CC BY},
}
RIS
TY - JOUR
TI - Heart-reactive antibody levels differentially associate with ventricular function in hereditary cardiomyopathies
AU - Dennis Schiffer
AU - Boshra Afshar
AU - Daria Grosser
AU - Juliana Pet
AU - Lena Schmidbauer
AU - Maximilian Bauser
AU - Gustavo Ramos
AU - Valerie Boivin-Jahns
AU - Roland Jahns
AU - Stefan Frantz
AU - Peter Heuschmann
AU - Stefan Störk
AU - Brenda Gerull
AU - Niklas Beyersdorf
AU - Caroline Morbach
PY - 2026
DA - 2026/10/25
JO - BMC Cardiovascular Disorders
DO - 10.1186/s12872-026-06808-3
UR - https://doi.org/10.1186/s12872-026-06808-3
AB - Background gCMP are a major cause of cardiovascular morbidity and mortality. While agonistic anti-β1-adrenergic receptor antibodies (anti-β1AR-ECII) have a recognized pathogenic role in idiopathic dilated cardiomyopathy (DCM), the relevance of HRA in gCMP remains unclear. Methods One hundred gCMP patients with confirmed genetic variants in cardiomyopathy genes were compared with 100 age- and sex-matched healthy individuals. Antibody reactivities were quantified using bead-based flow cytometric assays against cardiac antigens: The second extracellular loop of the β1 adrenergic receptor (β1AR-ECII), Troponin I3 (TPI3), Tropomyosin 1 (TPM1), Myosin heavy chain 6 and 7 (MYH6, MYH7) and Myosin light chain 7 (MYL7). Results gCMP patients showed higher anti-TPI3 and lower anti-TPM1 antibody levels compared to controls indicating increased induction of the former and loss of the latter in gCMP patients. Age and sex influenced HRA patterns in both groups. Anti-MYH6 and anti-TPM1 antibody levels were negatively associated with left ventricular ejection fraction (LVEF), both overall and within specific gCMP subtypes, including hypertrophic and arrhythmogenic cardiomyopathy. Additionally, anti-MYH6 antibody levels were negatively associated with right ventricular function, measured by tricuspid annular plane systolic excursion (TAPSE). Conclusion Our findings stress the diagnostic potential of HRA profiling and indicate that gCMP patients might profit from therapeutic targeting of HRA.
SN - 1471-2261
ER -